In the presence of immune checkpoint inhibitors targeting the CTLA-4/CD80 and PD-1/PDL-1 signaling pathways, these pathways are inhibited, and T cells are reactivated, leading to the death of cancer cells (30). Here, CD80 is linked to cancer.